178 filings
Page 4 of 9
8-K
53mmu4sb2 g6lfav
27 Jan 21
Departure of Directors or Certain Officers
4:06pm
8-K
ig5 pbj7rii
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
mq04cdqmjms
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
pxf00f89cnxez o7
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
enz6 tk9eb6yh
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
s8bil
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
18ect sihlqyya41y
17 Sep 20
Departure of Directors or Certain Officers
7:05am
8-K
7jj6ekp9ycmfnqjvyc
15 Sep 20
Other Events
4:11pm
8-K
u8ank3t
14 Sep 20
Submission of Matters to a Vote of Security Holders
4:59pm
8-K
pol0lbjlid
4 Sep 20
Entry into a Material Definitive Agreement
4:32pm
8-K
yhji5l 4wvq0qb
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
jky0 ycvx8a5jjo
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
355zikx wsidas60
6 May 20
Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
facl 752l94cq
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
lq0t3ht5 h0gt7colzxw
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
t529n jalnop2l
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
5zlcwhcsypb93g
13 Jan 20
Other Events
8:06am
8-K
wh62i9 x78tk
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
eybf 2ldx3oy5
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
ny9qc0
2 Dec 19
Other Events
5:18pm